Skip to main content
Clinical Trials/NCT06020326
NCT06020326RecruitingNot Applicable

A Retrospective Cohort Study of Hemorrhagic Fever With Renal Syndrome

Tongji Hospital8 sites in 1 country500 target enrollmentStarted: May 5, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
500
Locations
8
Primary Endpoint
short-term mortality

Study Overview

Brief Summary

The goal of this retrospective cohort study is to learn about the clinial characteristics of HFRS patients, explore the risk factors of the occurrence and death of HFRS, and build a risk prediction model for HFRS.

Detailed Description

HFRS remains an important public health issue in China, which not only poses a threat to people's physical health and safety, but also has a serious impact on social and economic development. At present, there is no unified standard for clinical prediction of the occurrence and death of HFRS. In order to better prevent and treat HFRS, this multicenter retrospective clinical study is designed to include HFRS inpatients, and collect their demographics, epidemiological history, hospitalization information, clinical manifestation, laboratory results, imaging results, treatment plan and outcome.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • The patients must meet all of the following criteria:
  • Inpatient with clinical diagnosis of Haemorrhagic Fever with Renal Syndrome

Exclusion Criteria

  • Exclude patients who meet any of the following criteria:
  • Patients with previous chronic kidney disease
  • Pregnant or perinatal patients
  • Patients unsuitable for inclusion by investigators' evaluation

Outcomes

Primary Outcomes

short-term mortality

Time Frame: 90 days post diagnosed HFRS

28-day and 90-day mortality after diagnosed as HFRS

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Qin Ning

Director, Department of Infection

Tongji Hospital

Study Sites (8)

Loading locations...

Similar Trials